ADI-001 is a CAR T cell therapy that targets CD20 to treat autoimmune diseases. Fast Track Designation is intended to accelerate the development and regulatory review of drugs aimed at treating ...

Shares of NASDAQ ADI opened at $238.91 on Thursday. The stock has a market cap of $118.49 billion, a P/E ratio of 76.09, a P/E/G ratio of 2.60 and a beta of 1.04.

Investing.com -- Adicet Bio shares jumped 6.4% premarket after the company announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to its investigational therapy ...